Clinical Trial Update: BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study [Phase 1]

View source ↗

Summary

Phase 1 study of BAY1003803 in psoriasis was terminated. The trial evaluated single- and multiple-dose escalation, safety, tolerability, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• BAY1003803

Snippet

Sponsor: Bayer | Conditions: Psoriasis | Phase 1 | Status: TERMINATED